Highlights Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
16.79 ^USD	+0.18%		+39.11%	+49.91%

May. 15	B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	MT
May. 14	Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours	May. 13	MT
Harrow, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Top Midday Decliners	Mar. 20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	Jan. 03	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03	MT
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	Nov. 29	CI
Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday	Nov. 14	MT
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours	Nov. 13	MT
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023	Nov. 13	CI
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	Nov. 13	CI
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S	23-10-24	CI
Harrow Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Harrow Launches VIGAMOX in the U.S	23-07-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Harrow, Inc.

Equities

HROW

US4158581094

Highlights

Filters